Annette Reichardt

Adjuvant Imatinib for High-Risk GI Stromal Tumor: Analysis of a Randomized Trial

Heikki Joensuu, Mikael Eriksson, Kirsten Sundby Hall et al. · Journal of Clinical Oncology · 2015 · 231 citations

Medicine, Oncology, Immunotherapy +14

Effect of <i>KIT</i> and <i>PDGFRA</i> Mutations on Survival in Patients With Gastrointestinal Stromal Tumors Treated With Adjuvant Imatinib

Heikki Joensuu, Eva Wardelmann, Harri Sihto et al. · JAMA Oncology · 2017 · 188 citations · Full text

Medicine, Oncology, Pharmacotherapy +16

Survival Outcomes Associated With 3 Years vs 1 Year of Adjuvant Imatinib for Patients With High-Risk Gastrointestinal Stromal Tumors

Heikki Joensuu, Mikael Eriksson, Kirsten Sundby Hall et al. · JAMA Oncology · 2020 · 180 citations · Full text

Medicine, Oncology, Surgery +15

A Phase I Study of Single-Agent Nilotinib or in Combination with Imatinib in Patients with Imatinib-Resistant Gastrointestinal Stromal Tumors

George D. Demetri, Paolo G. Casali, Jean‐Yves Blay et al. · Clinical Cancer Research · 2009 · 110 citations · Full text

Pharmacy, Clinical Pharmacokinetics, Pharmacology +11

Twelve versus 36 months of adjuvant imatinib (IM) as treatment of operable GIST with a high risk of recurrence: Final results of a randomized trial (SSGXVIII/AIO).

Heikki Joensuu, Mikael Eriksson, J. Hatrmann et al. · Journal of Clinical Oncology · 2011 · 79 citations

Medicine, Oncology, Surgery +13